Waxman’s Biogenerics Bill Limits Patent Infringement Damages

Brand manufacturers would only be entitled to a “reasonable” royalty when a biogeneric or biosimilar company’s product is found to have infringed on a company’s patents, according to a provision in Rep. Henry Waxman’s (D-Calif.) biogenerics bill. Under House legislation, brand companies would be required to respond to requests from generic companies for information on patents covering their biologic products.
Drug Industry Daily